{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:02:30Z","timestamp":1766088150750},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"David Orgler Fund for Cancer Research"},{"name":"NIH","award":["CA249180; GM097455"],"award-info":[{"award-number":["CA249180; GM097455"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previously, we have identified a novel human metastasis-inducing lncRNA (named SKAI1BC), that suppresses the KAI1\/CD82 metastasis-suppressing gene and is upregulated in triple negative breast cancer and melanoma derived cell lines. Modeling of the SKAI1BC lncRNA secondary structure and its potential interaction with Inforna compounds, led us to identify several compounds that might bind the SKAI1BC lncRNA. We found that these compounds inhibit metastasis invasion and cell migration in culture, in all eight types of solid human cancers tested: several of which are the most lethal and\/or frequent human malignancies. Moreover, in most cases, the mechanism of action of several of our compounds involves enhancement of KAI1\/CD82 RNA level depending on the specific compound and the human tumor type. With the epigenetic inactivation of KAI1\/CD82 in at least ten additional solid human cancers, this implies a very good chance to broaden the spectrum of human cancers affected by our compounds. This is the first time that modeling of a large lncRNA (&gt;\u2009700\u00a0bp) secondary structure followed by its potential interaction with Inforna like compounds database has led to the identification of potential biologically active small molecule drugs.<\/jats:p>","DOI":"10.1038\/s41598-023-47478-x","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:03:09Z","timestamp":1700600589000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors"],"prefix":"10.1038","volume":"13","author":[{"given":"Pnina Gottfried","family":"Komlosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Childs-Disney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Disney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Canaani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"47478_CR1","doi-asserted-by":"publisher","first-page":"D135","DOI":"10.1093\/nar\/gky1031","volume":"47","author":"PJ Volders","year":"2019","unstructured":"Volders, P. J. et al. LNCipedia 5: Towards a reference set of human long non-coding RNAs. Nucleic Acids Res. 47, D135\u2013D139 (2019).","journal-title":"Nucleic Acids Res."},{"key":"47478_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000258","volume":"4","author":"KV Morris","year":"2008","unstructured":"Morris, K. V., Santoso, S., Turner, A. M., Pastori, C. & Hawkins, P. G. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet. 4, e1000258 (2008).","journal-title":"PLoS Genet."},{"key":"47478_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature06468","volume":"451","author":"W Yu","year":"2008","unstructured":"Yu, W. et al. Epigenetic silencing of tumor suppressor gene p15 by its antisense RNA. Nature 451, 202\u2013206 (2008).","journal-title":"Nature"},{"key":"47478_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2174\/1574892813666180226121819","volume":"13","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. & Tang, L. The application of lncRNAs in cancer treatment and diagnosis. Anticancer Drug Discov. 13, 292\u2013301 (2018).","journal-title":"Anticancer Drug Discov."},{"key":"47478_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrg3722","volume":"15","author":"KV Morris","year":"2014","unstructured":"Morris, K. V. & Mattick, J. S. The rise of regulatory RNA. Nat. Rev. Genet. 15, 423\u2013437 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"47478_CR6","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.2147\/OTT.S150349","volume":"10","author":"J Zhu","year":"2017","unstructured":"Zhu, J. et al. Prognostic role of CD82\/KAI1 in multiple human malignant neoplasms: A meta-analysis of 31 studies. Onco Targets Ther. 10, 5805\u20135816 (2017).","journal-title":"Onco Targets Ther."},{"key":"47478_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10555-015-9585-x","volume":"34","author":"J Feng","year":"2015","unstructured":"Feng, J. et al. Tetraspanin CD82: A suppressor of solid tumors and a modulator of membrane heterogeneity. Cancer Metastasis Rev. 34, 619\u2013632 (2015).","journal-title":"Cancer Metastasis Rev."},{"key":"47478_CR8","doi-asserted-by":"publisher","first-page":"9924473","DOI":"10.1155\/2021\/9924473","volume":"2021","author":"W Yan","year":"2021","unstructured":"Yan, W., Huang, J., Zhang, Q. & Zhang, J. Role of metastasis suppressor KAI1\/CD82 in different cancers. J. Oncol. 2021, 9924473 (2021).","journal-title":"J. Oncol."},{"key":"47478_CR9","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.3390\/cancers13174486","volume":"13","author":"M Viera","year":"2021","unstructured":"Viera, M., Yip, G. W. C., Shen, H. M., Baeg, G. H. & Bay, B. H. Targeting CD82\/KAI1 for precision therapeutics in surmounting metastatic potential in breast cancer. Cancers 13, 4486 (2021).","journal-title":"Cancers"},{"key":"47478_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ab.2013.03.031","volume":"439","author":"S Tzadok","year":"2013","unstructured":"Tzadok, S., Caspin, Y., Hachmo, Y., Canaani, D. & Dotan, I. Directionality of noncoding human RNAs: How to avoid artifacts. Anal. Biochem. 439, 23\u201329 (2013).","journal-title":"Anal. Biochem."},{"key":"47478_CR11","doi-asserted-by":"publisher","first-page":"67538","DOI":"10.18632\/oncotarget.18733","volume":"8","author":"R Aram","year":"2017","unstructured":"Aram, R., Dotan, I., Hotz-Wagenblatt, A. & Canaani, D. Identification of a novel metastasis inducing lncRNA which suppresses the KAI1\/CD82 metastasis suppressor gene and is upregulated in triple-negative breast cancer. Oncotarget 8, 67538\u201367552 (2017).","journal-title":"Oncotarget"},{"key":"47478_CR12","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.3390\/ijms22073295","volume":"22","author":"H Xiong","year":"2021","unstructured":"Xiong, H., Veedu, R. N. & Diermeir, S. D. Recent advances in oligonucleotide therapeutics in oncology. Int. J. Mol. Sci. 22, 3295 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"47478_CR13","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41573-022-00521-4","volume":"21","author":"JL Childs-Disney","year":"2022","unstructured":"Childs-Disney, J. L. et al. Targeting RNA structures with small molecules. Nat. Rev. Drug Discov. 21, 736\u2013762 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"47478_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nchembio.1452","volume":"10","author":"SP Velagapudi","year":"2014","unstructured":"Velagapudi, S. P., Gallo, S. M. & Disney, M. D. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat. Chem. Biol. 10, 291\u2013297 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"47478_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1021\/acschembio.6b00001","volume":"11","author":"MD Disney","year":"2016","unstructured":"Disney, M. D. et al. Inforna 2.0: A Platform for the sequence-based design of small molecules targeting structured RNA. ACS Chem. Biol. 11, 1720\u20131728 (2016).","journal-title":"ACS Chem. Biol."},{"key":"47478_CR16","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1021\/jacs.8b01233","volume":"140","author":"MG Costales","year":"2018","unstructured":"Costales, M. G., Matsumoto, Y., Velagapudi, S. P. & Disney, M. D. Small molecule targeted recruitment of a nuclease to RNA. J. Am. Chem. Soc. 140, 6741\u20136744 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"47478_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","volume":"6","author":"HS Haniff","year":"2020","unstructured":"Haniff, H. S. et al. Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders. ACS Cent. Sci. 6, 1713\u20131721 (2020).","journal-title":"ACS Cent. Sci."},{"key":"47478_CR18","doi-asserted-by":"publisher","first-page":"20815","DOI":"10.1021\/jacs.2c08770","volume":"144","author":"BM Suresh","year":"2022","unstructured":"Suresh, B. M. et al. Low-molecular weight small molecules can potently bind RNA and affect oncogenic pathways in cells. J. Am. Chem. Soc. 144, 20815\u201320824 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"47478_CR19","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1039\/D0CS00560F","volume":"49","author":"SM Meyer","year":"2020","unstructured":"Meyer, S. M. et al. Small molecule recognition of disease-relevant RNA structures. Chem. Soc. Rev. 49, 7167\u20137199 (2020).","journal-title":"Chem. Soc. Rev."},{"key":"47478_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle, M., El-Daly, S. M., Fabbri, M. & Calin, G. A. Noncoding RNA therapeutics\u2014Challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629\u2013651 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"47478_CR21","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.6136","volume":"6","author":"RJ Andrews","year":"2018","unstructured":"Andrews, R. J., Roche, J. & Moss, W. N. ScanFold: An approach for genome-wide discovery of local RNA structural elements-applications to Zika virus and HI. PeerJ 6, e6136 (2018).","journal-title":"PeerJ"},{"key":"47478_CR22","doi-asserted-by":"publisher","first-page":"659963","DOI":"10.3389\/fonc.2021.659963","volume":"11","author":"S Sauer","year":"2021","unstructured":"Sauer, S. et al. Innovative approaches in the battle against cancer recurrence: Novel strategies to combat dormant disseminated tumor cells. Front. Oncol. 11, 659963 (2021).","journal-title":"Front. Oncol."},{"key":"47478_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.trecan.2017.04.008","volume":"3","author":"A Gandalovvicova","year":"2017","unstructured":"Gandalovvicova, A. et al. Migrastatics-anti-metastatic and anti-invasion drugs: Promises and challenges. Trends Cancer 3, 391\u2013406 (2017).","journal-title":"Trends Cancer"},{"key":"47478_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2020.151075","volume":"99","author":"V Cermak","year":"2020","unstructured":"Cermak, V. et al. Microtubule-targeting agents and their impact on cancer treatment. Eur. J. Cell Biol. 99, 151075 (2020).","journal-title":"Eur. J. Cell Biol."},{"key":"47478_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41416-021-01442-6","volume":"125","author":"O Maiques","year":"2021","unstructured":"Maiques, O. et al. A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma. BJC 125, 699\u2013713 (2021).","journal-title":"BJC"},{"key":"47478_CR26","doi-asserted-by":"publisher","first-page":"13242","DOI":"10.1002\/anie.201808823","volume":"57","author":"A Donlic","year":"2018","unstructured":"Donlic, A. et al. Discovery of small molecule ligands for MALAT1 by tuning an RNABinding scaffold. Angew. Chem. Int. Ed. 57, 13242\u201313247 (2018).","journal-title":"Angew. Chem. Int. Ed."},{"key":"47478_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1021\/acschembio.8b00807","volume":"14","author":"FA Abulwerdi","year":"2019","unstructured":"Abulwerdi, F. A. et al. Selective small-molecule targeting of a triple helix encoded by the long noncoding RNA MALAT1. ACS Chem. Biol. 14, 223\u2013235 (2019).","journal-title":"ACS Chem. Biol."},{"key":"47478_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymeth.2019.11.001","volume":"183","author":"RJ Andrews","year":"2020","unstructured":"Andrews, R. J., Baber, L. & Moss, W. N. Mapping the RNA structural landscape of viral genomes. Methods 183, 57\u201367 (2020).","journal-title":"Methods"},{"key":"47478_CR29","doi-asserted-by":"publisher","first-page":"e14361","DOI":"10.7717\/peerj.14361","volume":"10","author":"RJ Andrews","year":"2022","unstructured":"Andrews, R. J., Rouse, R. B., O\u2019Leary, C. A., Booher, N. J. & Moss, W. N. ScanFold 2.0 rapid approach for identifying potential structured RNA targets in genomes and transcriptomes. PeerJ 10, e14361 (2022).","journal-title":"PeerJ"},{"key":"47478_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1748-7188-6-26","volume":"6","author":"R Lorenz","year":"2011","unstructured":"Lorenz, R. et al. ViennaRNA Package 2.0. Algorithms Mol. Biol. 6, 26 (2011).","journal-title":"Algorithms Mol. Biol."},{"key":"47478_CR31","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1261\/rna.053694.115","volume":"22","author":"MF Sloma","year":"2016","unstructured":"Sloma, M. F. & Mathews, D. H. Exact calculation of loop formation probability identifies folding motifs in RNA secondary structures. RNA 22, 1808\u20131818 (2016).","journal-title":"RNA"},{"key":"47478_CR32","doi-asserted-by":"publisher","first-page":"lqab127","DOI":"10.1093\/nargab\/lqab127","volume":"4","author":"WB Rouse","year":"2022","unstructured":"Rouse, W. B. et al. Prediction and analysis of functional RNA structures within the integrative genomics viewer. NAR Genom. Bioinform. 4, lqab127 (2022).","journal-title":"NAR Genom. Bioinform."},{"key":"47478_CR33","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/bioinformatics\/btp250","volume":"25","author":"K Darty","year":"2009","unstructured":"Darty, K., Denise, A. & Ponty, Y. VARNA: Interactive drawing and editing of the RNA secondary structure. Bioinformatics 25, 1974\u20131975 (2009).","journal-title":"Bioinformatics"},{"key":"47478_CR34","first-page":"264","volume":"12","author":"CJ Fong","year":"1992","unstructured":"Fong, C. J., Sutkowski, D. M., Kozlowski, J. M. & Lee, C. Utilization of the Boyden chamber to further characterize in vitro migration and invasion of benign and malignant human prostatic epithelial cells. Invasion Metastasis 12, 264\u2013274 (1992).","journal-title":"Invasion Metastasis"},{"key":"47478_CR35","first-page":"3239","volume":"47","author":"A Albini","year":"1987","unstructured":"Albini, A. et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47, 3239\u20133245 (1987).","journal-title":"Cancer Res."},{"key":"47478_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"47478_CR37","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"47478_CR38","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47478-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47478-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47478-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T09:23:01Z","timestamp":1700644981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47478-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47478"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47478-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"16 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D. is a founder of Expanion Therapeutics. The other four authors do not have any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20420"}}